Cover Image
市場調查報告書

女性的性功能障礙:開發中產品分析

Female Sexual Dysfunction - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192588
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
女性的性功能障礙:開發中產品分析 Female Sexual Dysfunction - Pipeline Review, H2 2017
出版日期: 2017年12月29日 內容資訊: 英文 74 Pages
簡介

所謂女性的性功能障礙是指在一般性行為方面,部分或全部生理階段性無法體驗健全經驗的情況。主要的因素有憂鬱症和焦慮症、心臟·血管疾病、肝臟或腎臟障礙、特定藥物(抗憂鬱藥,高血壓藥等)等。治療方法有進行雌激素療法。

本報告提供女性的性功能障礙治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

女性的性功能障礙概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Apricus Biosciences, Inc.
  • Emotional Brain BV
  • EndoCeutics, Inc.
  • M et P Pharma AG
  • Palatin Technologies, Inc.
  • Re-Pharm Limited
  • TherapeuticsMD, Inc.
  • Valeant Pharmaceuticals International, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10038IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2017, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 8, 5 and 3 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Female Sexual Dysfunction - Overview
  • Female Sexual Dysfunction - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Female Sexual Dysfunction - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Female Sexual Dysfunction - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Callitas Therapeutics Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • Fabre-Kramer Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • M et P Pharma AG
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • Re-Pharm Ltd
  • S1 Biopharma Inc
  • Strategic Science & Technologies LLC
  • TherapeuticsMD Inc
  • Female Sexual Dysfunction - Drug Profiles
  • (buspirone hydrochloride + testosterone) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (sildenafil citrate + testosterone) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bremelanotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • estradiol acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FKW-00GA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • gepirone hydrochloride ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • prasterone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVT-011 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S1B-3006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S1B-307 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sildenafil citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SIP-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Sexual Dysfunction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tadalafil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TBS-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WC-3011 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Female Sexual Dysfunction - Dormant Projects
  • Female Sexual Dysfunction - Discontinued Products
  • Female Sexual Dysfunction - Product Development Milestones
  • Featured News & Press Releases
  • Dec 19, 2017: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act Date for TX-004HR
  • Nov 29, 2017: TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
  • Nov 06, 2017: TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
  • Nov 03, 2017: TherapeuticsMD Provides Update on TX-004HR
  • Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission
  • Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-004HR at NAMS 2017
  • Sep 14, 2017: TherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR
  • Aug 10, 2017: TherapeuticsMD Provides Regulatory Update On TX-004HR
  • Jul 24, 2017: AMAG Pharmaceuticals Launches Intrarosa (prasterone) in the U.S. - a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause
  • Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA
  • Jul 17, 2017: TherapeuticsMD Provides Update on TX-004HR
  • Jul 14, 2017: M Pharmaceutical Provides Update on Extrinsa
  • Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction
  • May 08, 2017: TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
  • May 02, 2017: TherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Female Sexual Dysfunction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Female Sexual Dysfunction - Pipeline by Allergan Plc, H2 2017
  • Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H2 2017
  • Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2017
  • Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H2 2017
  • Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
  • Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2017
  • Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017
  • Female Sexual Dysfunction - Pipeline by Pivot Pharmaceuticals Inc, H2 2017
  • Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2017
  • Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H2 2017
  • Female Sexual Dysfunction - Pipeline by Strategic Science & Technologies LLC, H2 2017
  • Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2017
  • Female Sexual Dysfunction - Dormant Projects, H2 2017
  • Female Sexual Dysfunction - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Female Sexual Dysfunction - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Female Sexual Dysfunction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top